Company News
Icaritin Phase II advisory meeting held in Beijing: June 9th
Published：2013/6/13 18:26:29 Views：185
Shenogen held Ph II advisory meeting on June 9th in Beijing. Prominent Chinese Oncologists Drs. Yun Sun, Shukui Qin, Binghe Xu and Jianming Xu attended the meeting. The planned POC trial will enroll over 100-150 advanced hepatocellular carcinoma (HCC) patients in China and in Taiwan. Dr. Yun Sun, Academician of China Academy of Engineering and Dr. Shukui Qin, 2012 Chairman of Chinese Society of Clinical Oncology (CSCO) and Director of PLA Cancer Center, will serve as co-principal investigator for this study. For further information, please contact Chief Business Officer Jun Bao at jun.bao@shenogen.com